Pre-made Sotrovimab biosimilar ( Whole mAb, anti-SARS-CoV-2 Spike RBD therapeutic antibody) - benchmark reference antibody
Cat No.: GMP-Bios-ab-530
Anti-SARS-CoV-2 Spike RBD therapeutic antibody (Pre-made Sotrovimab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Sotrovimab is an investigational monoclonal antibody therapy medication with activity against SARS-CoV-2. It is under development by GlaxoSmithKline and Vir Biotechnology, Inc.
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Anti-SARS-CoV-2 Spike RBD therapeutic antibody (Pre-made Sotrovimab biosimilar,Whole mAb)|
|Target||SARS-CoV-2 Spike RBD|
|Highest_Clin_Trial (Jan '20)||Preregistration|
|100% SI Structure||None|
|99% SI Structure||7jx3:AB/6ws6:EF/6wps:CD:FG:HL/6wpt:DE:HL|
|95-98% SI Structure||None|